Clinical trialNCT06280950RecruitingPhase 2Interventional

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment340Liver Transplant

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Justin Boike, MD
Northwestern University Feinberg School of Medicine: Transplantation
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Hospital Arizona (site #: 71144)
Phoenix, Arizona, United States
Hugo Vargas, MD
Recruiting
Ronald Regan at Ucla Medical Center (site #: 71123)
Los Angeles, California, United States
Sammy Saab, MD
Not, yet, recruiting
University of California, San Diego (site #: 71179)
San Diego, California, United States
Pranab Barman, MD
Not, yet, recruiting
University of California, San Francisco (site #: 71108)
San Francisco, California, United States
Sandy Feng, MD
Recruiting
Northwestern University (site #: 71110)
Chicago, Illinois, United States
Justin Boike, MD →
Recruiting
University of Michigan (site #: 71154)
Ann Arbor, Michigan, United States
Justin Boike, MD →
Recruiting
Icahn School of Medicine at Mount Sinai (site #: 71115)
New York, New York, United States
Thomas Schiano, MD
Recruiting
Duke University Medical Center (site #: 71139)
Durham, North Carolina, United States
Matthew Kappus, MD
Recruiting
University of Pennsylvania (site #: 71111)
Philadelphia, Pennsylvania, United States
Abraham Shaked, MD
Recruiting
University of Pittsburgh Medical Center (site #: 71170)
Pittsburgh, Pennsylvania, United States
Scott Biggins, MD
Recruiting
Baylor Medical Center (site #: 71153)
Dallas, Texas, United States
Robert Rahimi, MD
Recruiting
Houston Methodist (site #: 71120)
Houston, Texas, United States
Mark Ghobrial, MD
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Everolimus →Tacrolimus →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Sept 2024
Primary completion: 30 Jun 2028
Completion: 30 Jun 2030
Last update posted: 17 Sept 2026
Registered enrollment: 340
Registry id: NCT06280950

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.